In the next 5 to 10 years, providers and health systems need to be thinking about how all the pieces of a new system that delivers holistic, value-based care fit together, said Will Shrank, MD, chief medical officer, Humana, during the opening plenary at the National Association of ACOs fall meeting.
Patients with psoriasis who were treated with biologics were less likely to develop psychiatric illnesses compared with patients not treated with biologics; however, the researchers did note treatment selection may have influenced the findings.
As minimal residual disease (MRD) and other measures to detect cancer burden are increasingly used to predict outcomes and direct future treatment decisions, Amgen has chosen to partner with Adaptive Biotechnologies to use the clonoSEQ product to assess MRD across multiple drug development programs.
Unsustainable healthcare costs are driving seismic changes to the way payers do business and are requiring the ability to extract deeper insights from data assets.
CMS is trying to make a 2-sided risk model in the Oncology Care Model enticing for practices, but there is still a lot of math practices need to work out before making the decision, said Blase Polite, MD, associate professor of medicine and the executive director for accountable care at the University of Chicago.
New research coming from Doximity is adding to the literature on the physician shortage's impact on maternity care, identifying which metropolitan areas are most likely to suffer from a shortage of obstetricians and gynecologists (OB/GYNs) in coming years.
Measurement of drug levels early in treatment with ustekinumab for patients with psoriasis may be able to successfully predict patient response and, therefore, direct a treatment strategy.
Migraines and cluster headaches can have devastating consequences on people’s lives, and there is a need to educate the public about the impact these disorders can have, said Abraham Nagy, MD, chair of neurology at University of Las Vegas and director of Nevada Headache Institute.
Novel therapies come with high costs, but they have the potential to more effectively treat some patients, and employers are struggling to handle the cost burden of them, said Michael Thompson, president and chief executive officer of the National Alliance of Healthcare Purchaser Coalitions.
Providing access to complex therapies through the Medicare market can benefit patients who are disproportionately ignored by socioeconomic status, said Scott Gottlieb, MD, former FDA commissioner (2017-2019).
Patients with polycythemia vera and essential thrombocythemia may be able to reduce their symptoms through a low-cost drug used to treat rheumatoid arthritis (RA), according to a new study in British Journal of Haematology.
Getting Americans in rural areas the right care at the right time is an issue that must be tackled at all levels. Ongoing efforts to coordinate care management and resources can prove beneficial for the rural communities that need it most.
CMS' new radiation oncology payment model is slated to begin on January 1, 2020, but the significant billing changes that the model requires will require more time.
Oncologists may be able to use circulating tumor DNA (ctDNA) to guide treatment decisions and predict which patients will have disease recurrence, according to 2 studies in JAMA Oncology.
To make headroom for expensive, potentially curative therapies in the pipeline, the healthcare needs to remove ineffective care from the system, said Susan Dentzer, visiting fellow at the Duke-Margolis Center for Health Policy.
Despite growing interest in addressing social determinants of health and recent research into interventions that address food insecurity, there are only a small number of low-quality studies in the area.
Healthcare does not necessarily need to be disrupted, but it does need to evolve and utilize technology so that cancer care can move beyond the conventional walls of the healthcare delivery system, said Susan Dentzer, visiting fellow at the Duke-Margolis Center for Health Policy, during her keynote speech at the Quality Cancer Care Alliance’s Leadership Summit.
As orphan drugs account for an increasing share of drugs approved, they are driving up the cost of drug launches and drug prices. In a new paper, America's Health Insurance Plans analyzes these rising costs and the use of orphan drugs and asserts that policy makers need to revisit the Orphan Drug Act.
Following the release of the latest accountable care organization (ACO) participation numbers from the CMS, the National Association of ACOs (NAACOS) authored its own take on the latest data around the Medicare Shared Savings Program, Medicare’s largest and most prominent value-based payment program serving 11 million patients.
Maria Trojano, MD, professor of neurology at the University of Bari, Italy, offered the opening lecture at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
A poster featuring a post-hoc exploratory analysis of measures of thalamic volume from RADIANCE was presented September 11, 2019, at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Real-world outcomes are important because the populations included in clinical trials rarely reflect the populations actually being treated in the clinic, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
Relationships in healthcare are important and trust is crucial to those relationships. However, it has been on the decline in the United States. We speak with the executive vice president of the ABIM Foundation and representatives from the 8 winning organizations of the foundation's Trust Practice Challenge about the programs they implemented to rebuild trust.
In 2 studies published in The Lancet Neurology, ozanimod was well tolerated and had a lower relapse rate in patients with relapsing multiple sclerosis.
The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the next new class of therapies probably won’t come to market for at least another year and a half, said Daniel Kantor, MD, president of Kantor Neurology.
